Tandem Therapeutics
Tandem Therapeutics is a Swiss biopharmaceutical company developing precision therapies targeting the extracellular matrix to treat fibrotic diseases.
About
Tandem Therapeutics is an early-stage Swiss biopharmaceutical company focused on bringing novel precision targeting approaches to treat fibrosis and fibrotic cancers. The company leverages over 15 years of transformative research and development in extracellular matrix biology, with origins at ETH Zürich and the Paul Scherrer Institute. Their therapeutic platform uses Matrix Targeting Peptides (MTP) that precisely target disease-associated matrix alterations, unlocking new druggable spaces previously inaccessible in fibrotic diseases. With a strong foundation in matrix mechanobiology, Tandem Therapeutics is developing a pipeline of selectively targeted, efficacious, and safe therapies primarily for progressive lung fibrosis, a fatal disease with no existing cures. The company has also been accepted into the Wyss Zurich Translational Center, benefitting from world-class infrastructure and expert support.
Products & Services
- Matrix Targeting Peptide (MTP) based therapies for fibrosis-driven diseases
- Pipeline of conditionally targeted therapies for fibrotic diseases
- Development of peptide drug conjugates for precision treatment
Use Cases & Case Studies
- Development and precision targeting of therapies for progressive lung fibrosis
- Translational R&D efforts in treating fatal fibrotic diseases
Partnerships & Collaborations
- Wyss Zurich Translational Center
- ETH Zürich
- Paul Scherrer Institute (PSI)
- Innosuisse
- ETH Foundation
- W.A. de Vigier Stiftung
- Venture Leaders Biotech Program
- Kantonsspital Baden (KSB)
- Charité
Awards & Recognition
- Winner of the W. A de Vigier Award 2024
- Top 15 nominees for the 2024 W. A de Vigier Award
- Selected for the 2023 Swiss National Startup Team for Venture Leaders Biotech Program, Boston